Tag Archives: cardiovascular risk

For decades, A1C has served as the cornerstone of diabetes management. It remains an essential marker because it reflects average blood glucose levels over approximately three months. However, many clinicians are recognizing that managing post-meal glucose levels may provide equally important insights into a patient’s metabolic health. A person can …

Poor sleep does more than leave people tired the next day. For many individuals living with diabetes, disrupted sleep may quietly worsen glucose control, increase cardiovascular risk, and complicate long-term metabolic health. As research continues to uncover the close relationship between sleep and metabolic function, more healthcare providers are referring …

More adults living with type 1 diabetes are now developing obesity, insulin resistance, hypertension, and metabolic complications once linked mainly to type 2 diabetes. This growing overlap, often called double diabetes, is becoming a major concern for clinicians and patients alike. While insulin therapy remains essential for type 1 diabetes …

Managing Type 2 diabetes used to follow a relatively predictable path. Clinicians often started with metformin and added medications gradually as glucose control worsened. Today, however, diabetes care looks very different. The number of available therapies has expanded rapidly, and while that growth has improved patient outcomes, it has also …

A patient loses 30 pounds, lowers their A1C, and improves their blood pressure within months of starting a GLP-1 medication. Stories like these are hard to ignore, and they have helped fuel growing enthusiasm around drugs like Ozempic, Wegovy, and Mounjaro. Yet as prescriptions continue to expand beyond high-risk diabetes …

GLP-1 therapies are becoming an important focus in peripheral artery disease, especially as clinicians look beyond glucose control to improve outcomes in high-risk patients. People with diabetes and peripheral artery disease often face a difficult path, marked by poor circulation, delayed wound healing, and a higher risk of amputation. While …

As GLP-1 therapies become a long-term cornerstone in diabetes care, monitoring patients on these treatments is gaining renewed attention. Clinicians once focused mainly on A1C and weight, but is that enough today? Much like checking only the speed of a car without looking at fuel or engine health, relying on …

Why do some patients still face heart risks even after managing blood sugar and cholesterol? This lingering issue has led researchers to explore how GLP-1 therapies may influence cardiovascular inflammation as a possible missing link. While traditional treatments focus on glucose and lipid control, growing evidence suggests inflammation may continue …

GLP-1 receptor agonists have reshaped the management of type 2 diabetes and obesity. However, growing interest now surrounds the potential role of GLP-1 therapy in normal-weight patients with cardiometabolic risk and whether treatment decisions should rely less on BMI alone. While body mass index remains a widely used screening tool, …